The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
DiaMedica said it plans to launch the trial later in 2026
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The company announced positive topline data from the Phase II ZUPREME-1 trial
Designed for intense clinical environments, Rembra can handle up to 270 exams per day
The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
The 6th Edition NABH framework places strong emphasis on patient safety protocols, robust clinical governance, risk management systems
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Subscribe To Our Newsletter & Stay Updated
